Brazil restructures healthcare products and suppliers inspectorate
This article was originally published in Clinica
The licensing and regulation in Brazil of healthcare products, their manufacturers and suppliers, as well as any related product marketing activities, will now be overseen by four new business units within the country's regulatory agency Anvisa.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.